Pilot Study Investigating a Restorative Wound Care Cream Together With Petrolatum on Surgical Excisions

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-05

Study Completion Date

2020-09-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The pilot study is prospective, randomized, double-blinded, with intra-subject comparisons against a vehicle control. The primary objective of this pilot study is to investigate the safety and effectiveness of a new wound care product formulated to improve healing outcome, minimize complications of impaired healing and minimize the appearance of scars.

This pilot study is double-blinded, which means that neither the evaluating physician nor the subject will know which treatment is administered.

Subjects' with 2 comparable excision sites will be randomly assigned to use the FS2 restorative wound care product on one excision site and a vehicle formulation of the product on the other. At the discretion of the Principal Investigator, a sutured wound may be bisected for intra-wound comparison of treatments. In all cases, after application of either vehicle or FS2, a layer of petrolatum will be applied to cover the wound site as a standard of care.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Scar Appearance After Postoperative Hydrocolloid Dressing Versus Standard Petrolatum Ointment

NCT05618912

Scar Skin Scarring Skin Cancer +6 more

COMPLETED NA

Zinc Oxide Versus Petrolatum Following Skin Surgery

NCT03561376

Surgical Incision Surgery--Complications Surgical Wound +3 more

RECRUITING EARLY_PHASE1

Autologous Fat Transfer for Scar Prevention and Remodeling

NCT01119326

Wound

COMPLETED PHASE1/PHASE2

Healing Ointment Usage Post-surgical Procedure

NCT05686928

Surgical Wound

COMPLETED PHASE4

Clinical Safety and Scar Prevention Study of a Topical Antifibrotic Compound FS2.

NCT04186273

Scar Cicatrix Hypertrophic Scar +4 more

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The pilot study is prospective, randomized, double-blinded, with intra-subject comparisons against a vehicle control. The primary objective of this pilot study is to investigate the safety and effectiveness of a new wound care product formulated to improve healing outcome, minimize complications of impaired healing and minimize the appearance of scars. Per protocol, study team members will investigate the efficacy of applying investigational product in combination with petrolatum on similar anatomically matched surgical excisions and bisected sutured wounds for a period of up to 180 days.

Secondary to direct complications that arise from removal of a skin lesion is the aesthetic disfigurement of tissue repair that results in a scar. The severity of even the most morbid scars is unpredictable and largely dependent on several variables. It is for this reason that this pilot study seeks to evaluate the application of a wound care product on both sutured and un-sutured surgical wounds across all phases of wound healing.

General and widely commercialized self-care (OTC) wound healing products include emollients, lotions, petrolatum creams, and topical antibiotics. With only a limited number of investigator-initiated studies, the advancement in this niche medical sector has been incremental across decades of research. This study is being undertaken to investigate the safety and effectiveness of a new cream product (FS2-cream) which was initially intended to manage hyperproliferative closed scars by maintaining an optimal skin environment. To obtain proof-of-concept results that enable the robust design of subsequent studies, we will obtain wound care metrics across all phases of healing and make intra-subject comparisons between the use of FS2-cream + petrolatum and vehicle-cream + petrolatum. We hypothesize that FS2-cream + petrolatum will show superior clinical outcomes compared to the vehicle control treatment.

This pilot study is double-blinded, which means that neither the evaluating physician nor the subject will know which treatment is administered. A separate study team member will administer the treatment as well as answer questions and discuss any problems throughout the study.

Subjects' with 2 comparable excision sites will be randomly assigned to use the FS2 restorative wound care product on one excision site and a vehicle formulation of the product on the other. At the discretion of the Principal Investigator, a sutured wound may be bisected for intra-wound comparison of treatments. In all cases, after application of either vehicle or FS2, a layer of petrolatum will be applied to cover the wound site as a standard of care.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Wound Heal Scar Keloid Surgical Wound

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The study consists of two (2) Treatments, both of which are administered in combination with petrolatum. The Treatments consist of either a restorative wound care cream (FS2 ingredient) or a vehicle wound care cream (without the FS2 ingredient).

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

This pilot study is double-blinded, which means that neither the evaluating physician nor the subject will know which treatment is administered. A separate study team member will administer the treatment as well as answer questions and discuss any problems throughout the study.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vehicle Cream Base Emulsion Moisturizer + Petrolatum

Group Type PLACEBO_COMPARATOR

Vehicle Cream Base Emulsion Moisturizer + Petrolatum

Intervention Type OTHER

Topical vehicle white (bone) color, oil/water emulsion moisturizer.

FS2 Emulsion Moisturizer + Petrolatum

Group Type EXPERIMENTAL

FS2 Emulsion Moisturizer + Petrolatum

Intervention Type OTHER

Topical FS2 white (bone) color, oil/water emulsion moisturizer.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vehicle Cream Base Emulsion Moisturizer + Petrolatum

Topical vehicle white (bone) color, oil/water emulsion moisturizer.

Intervention Type OTHER

FS2 Emulsion Moisturizer + Petrolatum

Topical FS2 white (bone) color, oil/water emulsion moisturizer.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female
2. Adult, Senior (\>18 years of age)
3. Healthy or medically stable
4. Requiring surgical removal (excision) of two (2) anatomically significantly similar areas and/or an excision of 3 - 10 cm in length suitable for intra-wound treatment comparison
5. Willing and able to follow study requirements

Exclusion Criteria

1. Subjects who are medically unstable
2. Subjects who are expected to be medically unstable for the duration of the study period and an additional 1-month thereafter
3. Pregnant subjects, or those attempting to become pregnant
4. Subjects with known immunosuppression or immunosuppressive illness
5. Subjects with uncontrolled diabetes or autoimmune disorders
6. Subjects with known sensitivity to ingredients in the test-treatment products
7. Any other diagnosis, condition, physical or geographical limitation that may render, or increases the likelihood of rendering, the Subject unable to complete the entire study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No